# US 2024/0197735 A1 · Methods and compositions comprising a braf inhibitor and a pd-1 binding antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197735 A1
- Document ID: US20240197735A1
- Status: Published application
- Kind: A1
- Application number: 18/533,539
- Filed: 2023-12-08
- Published: 2024-06-20
- Earliest claimed: 2021-06-09
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Jan ECKMANN; Thomas FRIESS; Frank HERTING; Piergiorgio Francesco Tommaso PETTAZZONI; Juergen WICHMANN
- Web page: https://patentgrep.com/patent/US20240197735A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a PD-1 axis binding anatgonist.

## Claims

### Claim 1

A combination of a BRAF inhibitor and a PD-1 axis binding antagonist, wherein the BRAF inhibitor is a compound of formula (I):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

The combination according to claim 1, wherein the compound of formula (I) is (3R)—N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide.

### Claim 3 (depends on 1)

The combination according to claim 1, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist and a PD-L2 binding antagonist.

### Claim 4 (depends on 1)

The combination according to claim 1, wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist.

### Claim 5 (depends on 1)

The combination according to claim 1, wherein the PD-1 axis binding antagonist is selected from the group consisting of cemiplimab, pembrolizumab, nivolumab, RN888, atezolizumab, avelumab and durvalumab.

### Claim 6 (depends on 1)

The combination according to claim 1, wherein the PD-1 axis binding antagonist is atezolizumab.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

A method for the treatment of cancer, the method comprising administering a pharmaceutically effective amount of a combination of a BRAF inhibitor and a PD-1 axis binding antagonist according to claim 1 to a patient in need thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a combination of a BRAF inhibitor and a PD-1 axis binding antagonist according to claim 1, and one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the BRAF inhibitor is administered orally and the PD-1 axis binding anatgonist is administered by injection, such as intravenous or subcutaneous injection.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the BRAF inhibitor is administered concurrently with the PD-1 axis binding antagonist.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the BRAF inhibitor is administered sequentially with the PD-1 axis binding antagonist.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the cancer is thyroid cancer, colorectal cancer, melanoma, brain cancer, leptomeningeal cancer or non-small cell lung cancer.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the cancer is associated with BRAFV600X mutations.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cancer is BRAFV600X mutation-positive unresectable or metastatic cancer.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the BRAFV600X mutation is determined using a method comprising (a) performing PCR or sequencing on nucleic acid extracted from a sample of the patient's tumour tissue and/or body fluid; and (b) determining expression of BRAFV600 in the sample.

### Claim 19 (depends on 10)

The method according to claim 10, the method further comprising administering one or more additional anticancer agents selected from the group consisting of MEK inhibitors, MEK degraders, EGFR inhibitors, EGFR degraders, inhibitors of HER2 and/or HER3, degraders of HER2 and/or HER3, SHP2 inhibitors, SHP2 degraders, Axl inhibitors, Axl degraders, ALK inhibitors, ALK degraders, PI3K inhibitors, PI3K degraders, SOS1 inhibitors, SOS1 degraders, signal transduction patway inhibitors, checkpoint inhibitors, modulators of the apoptosis pathway, cytotoxic chemotherapeutics, angiogenesis-targeted therapies, immune-targeted agents, and antibody-drug conjugates.

### Claim 20 (depends on 1)

The combination according to claim 1, the combination further comprising a MEK inhibitor.

### Claim 21

(canceled)
